JP4073430B2 - Nucleic acid recovery method - Google Patents

Description

  The present invention relates to a method for recovering nucleic acid from a sample containing ribonucleic acid and deoxyribonucleic acid. For example, the present invention relates to a nucleic acid recovery method capable of selectively recovering deoxyribonucleic acid (DNA) and / or ribonucleic acid (RNA).

  Patent Document 1 discloses that a nucleic acid is extracted by using silica particles capable of binding to a nucleic acid in the presence of a chaotropic substance as a solid phase for binding nucleic acid. In this Patent Document 1, a sample containing a nucleic acid is added to a reaction vessel containing a suspension of silica particles and a guanidine thiocyanate buffer as a chaotropic substance and mixed, and a complex in which the nucleic acid is bound to the silica particles is prepared. After sedimentation by centrifugation, the supernatant is discarded, and the remaining complex is washed with a washing solution. The reprecipitated complex is washed with an aqueous ethanol solution, then washed with acetone, and the acetone is removed and dried. A method of eluting and recovering nucleic acids by adding an elution buffer to the complex is described.

  Patent Document 2 discloses a nucleic acid purification method and a purification apparatus using a nucleic acid capture chip incorporating a silica-containing solid phase. In this method, a nucleic acid capturing chip is detachably connected to a liquid suction / discharge movable nozzle, and a mixture of a substance that promotes binding of nucleic acid to a solid phase and a nucleic acid-containing sample is transferred from a predetermined container to the liquid suction / discharge movable nozzle. After sucking into the connected nucleic acid capture chip and binding the nucleic acid to the solid phase, the liquid in the nucleic acid capture chip is removed, and then the inside of the nucleic acid capture chip is washed by sucking and discharging the washing liquid, and then washed. The eluent is sucked into the later nucleic acid capturing chip, and the eluent containing the nucleic acid eluted from the solid phase is discharged into the purified product container.

  Furthermore, Patent Document 3 discloses a method for extracting and purifying RNA using a nucleic acid binding carrier. In this method, a biological solution such as cells is added to a biological material by adding, mixing, or contacting a lysate containing a chaotropic substance, an extract composed of an organic solvent, and a nucleic acid-binding solid phase carrier under acidic conditions. The contained RNA is adsorbed onto the solid phase, the solid phase carrier is washed with a washing solution, and the RNA is eluted with an elution solution.

  Furthermore, Patent Document 4 discloses a method for isolating ribonucleic acid using a nucleic acid binding carrier. In this method, a sample containing RNA, an acidic solution containing a chaotropic agent, a water-soluble organic solvent and a nucleic acid binding carrier are mixed to adsorb RNA to the carrier, and the carrier-RNA complex is separated from the liquid phase. If necessary, the carrier-RNA complex is washed, and RNA is eluted from the carrier-RNA complex.

Patent 2680462 Japanese Patent Laid-Open No. 11-266864 JP-A-9-327291 JP-A-11-196869

  The method described in Patent Document 1 and the method described in Patent Document 2 are collected in a mixed state of DNA and RNA. For this reason, in order to obtain DNA independently, the further isolation | separation or an enzyme process etc. are needed.

  Further, in the method described in Patent Document 3 and the method described in Patent Document 4, since DNA is removed as an unadsorbed component in a series of steps, it is impossible to isolate DNA together with RNA from the same sample.

  In any of the methods described in Patent Documents 1 to 4, in order to obtain a purified DNA solution that does not contain RNA from one sample, a special treatment for removing RNA is required. In other words, in the methods described in Patent Documents 1 to 4, it is necessary to separately collect DNA and RNA using a plurality of protocols by subdividing the same sample. Thus, conventionally, when it is necessary to isolate and purify DNA or RNA from one sample, a very complicated process is required, and the efficiency is very poor.

  Therefore, an object of the present invention is to provide a nucleic acid recovery method that can efficiently recover deoxyribonucleic acid and / or ribonucleic acid from a sample containing ribonucleic acid and deoxyribonucleic acid.

  The present invention relates to a nucleic acid recovery method in which a low-temperature eluent is brought into contact with a nucleic acid-capturing substance that has captured ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). The recovery rate of RNA and DNA by the eluent varies depending on the temperature of the eluent, but the recovery rate of DNA is dramatically larger than the recovery rate of RNA in the low temperature eluent. Thereby, DNA can be efficiently recovered from a sample containing RNA and DNA.

  The present invention also relates to a nucleic acid recovery method in which a first eluent is brought into contact with a nucleic acid-capturing substance that has captured RNA and DNA, and then a second eluent having a temperature higher than that of the first eluent is brought into contact. By the first eluent, DNA is mainly eluted from the nucleic acid capture substance, and RNA is mainly captured by the nucleic acid capture substance. Then, RNA is mainly eluted from the nucleic acid capture substance by the second eluent. Thereby, DNA and RNA can be selectively recovered from one sample.

  The present invention also relates to a nucleic acid recovery method in which a reagent for reducing RNA is added to a first eluent from which DNA has been mainly eluted. Since the amount of RNA eluted in the first eluent is very small, high-purity DNA can be recovered even with a small amount of reagent that reduces RNA.

  The present invention also relates to a nucleic acid recovery method in which a reagent for reducing DNA is added to a second eluent from which RNA has been mainly eluted. Since the amount of DNA eluted in the second eluent is very small, high-purity RNA can be recovered even with a small amount of reagent that reduces DNA.

  The above and other novel features and effects of the present invention will be described below with reference to the drawings.

  According to the present invention, deoxyribonucleic acid and / or ribonucleic acid can be efficiently recovered from a sample containing deoxyribonucleic acid and ribonucleic acid.

  The nucleic acid recovery method according to the present invention includes a first step of contacting a nucleic acid-binding solid phase with a sample containing ribonucleic acid and deoxyribonucleic acid, and a nucleic acid-binding solid phase capturing ribonucleic acid and deoxyribonucleic acid contained in the sample. In the first eluent, the temperature is equal to or higher than the temperature at which deoxyribonucleic acid can be effectively eluted from the nucleic acid-binding solid phase, and lower than the temperature at which ribonucleic acid can be effectively eluted from the nucleic acid-binding solid phase. And a second step of processing within the temperature range.

  A specific flowchart of the nucleic acid recovery method is shown in FIG. As shown in FIG. 1, in the nucleic acid recovery method, first, in step 1, release of nucleic acid from a nucleic acid-containing substance is promoted. Here, the nucleic acid-containing substance means a sample containing deoxyribonucleic acid (hereinafter referred to as DNA) and ribonucleic acid (hereinafter referred to as RNA). For example, biological samples such as whole blood, serum, sputum and urine, cultured cells, cultured bacteria Or a biological sample such as a nucleic acid, a nucleic acid held in a gel after electrophoresis, a reaction product such as a DNA amplification enzyme, or a substance containing nucleic acid in a roughly purified state. The nucleic acid herein includes double-stranded, single-stranded, or DNA and RNA having a partially double-stranded or single-stranded structure.

  In order to promote the release of nucleic acid from a nucleic acid-containing substance, it means that a solution containing the nucleic acid-containing substance is prepared under conditions that facilitate the release of nucleic acid from the nucleic acid-containing substance. Although this condition is not specifically limited, For example, it can achieve by adding the reagent which accelerates | stimulates release of a nucleic acid to the solution containing a nucleic acid containing substance. The reagent is not particularly limited, but it is not desirable to use a highly viscous substance. For example, a protease such as protease K, a surfactant such as sodium dodecyl sulfate, or a chaotropic reagent such as guanidinium salt can be used. . In addition, when the nucleic acid to be collected is RNA, it is desirable to add an RNase inhibitor or guanidine thiocyanate to the solution containing the nucleic acid-containing substance in order to prevent the action by RNase.

  Next, in step 2, a reagent that promotes the binding between the nucleic acid released in the solution in step 1 and the nucleic acid-binding solid phase that is brought into contact with the solution in the next step is added to the solution prepared in step 1. . The reagent used in Step 2 is not particularly limited. However, when the nucleic acid-binding solid phase contains silica, it is particularly preferable to use a chaotropic reagent (for example, guanidine-HCl). In Step 2, when the target of nucleic acid recovery is RNA, it is desirable to add guanidine thiocyanate for the same reason as in Step 1. The final concentration of guanidine thiocyanate is 3 mol / L or more and the final pH is acidic. It is desirable to do. Alternatively, as described in Patent Document 1, Step 1 and Step 2 can be performed collectively.

  Next, in step 3, the solution prepared in step 2 is brought into contact with the nucleic acid-binding solid phase. The nucleic acid-binding solid phase is not particularly limited as long as it is a substance capable of immobilizing nucleic acid on the surface. For example, glass particles, silica particles, quartz filter paper and crushed materials thereof, silica oxides such as quartz wool and diatomaceous earth are used. The substance to be contained, or a material such as plastic coated with silica can be used. In particular, the nucleic acid-binding solid phase is preferably one containing silica, that is, silicon dioxide.

  When the nucleic acid-binding solid phase is used in the form of particles or granules, in step 3, the particles or granules are mixed in the solution prepared in step 2 and stirred to bind the solution prepared in step 2 and nucleic acid binding. The solid phase can be contacted. On the other hand, when the nucleic acid-binding solid phase is used by being disposed in the nucleic acid capture chip 100 as shown in FIG. 2, in step 3, the solution prepared in step 2 is repeatedly sucked and discharged in the nucleic acid capture chip 100. Thus, the solution prepared in Step 2 can be brought into contact with the nucleic acid-binding solid phase.

  Specifically, as shown in FIG. 2, the nucleic acid capture chip 100 has an inner diameter that is airtightly fitted to a pipette nozzle (not shown) that is used in combination with the head 103, and the lower part is at the tip 104. The nucleic acid-binding solid phase 102 is provided on the tip side. In addition, a disc-shaped blocking member 101 a for preventing the nucleic acid-binding solid phase 102 from flowing out to the front end side of the nucleic acid-capturing chip 100 and for defining the average interval between the nucleic acid-binding solid phases 102. And a disc-shaped blocking member 101b on the head 103 side so that the nucleic acid-binding solid phase 102 has a predetermined average interval. These blocking members 101 a and 101 b have a large number of holes through which liquid and gas can easily pass, and the holes are sized to prevent the nucleic acid-binding solid phase 102 from flowing out.

  The nucleic acid capture chip 100 is made of a transparent or translucent synthetic resin. As the material of the blocking members 101a and 101b, a material obtained by sintering quartz particles having a diameter of about 0.1 mm into a shape matching the inner diameter of a predetermined position of the nucleic acid capturing chip 100 is used. As the nucleic acid-binding solid phase 102, for example, quartz wool (manufactured by Toshiba Chemical, grade B) is used.

  Next, in Step 4, the nucleic acid-binding solid phase is separated from the solution, and the nucleic acid-binding solid phase is washed. When using a nucleic acid-binding solid phase in the form of particles or granules, after mixing and stirring in step 3, for example, remove only the solution with a suction device etc. to separate the nucleic acid-binding solid phase from the solution Can do. When the nucleic acid binding solid phase disposed inside the nucleic acid capture chip 100 is used, the nucleic acid binding solid phase and the solution can be separated by discharging the solution accumulated in the nucleic acid capture chip 100. .

  In Step 4, after separating the nucleic acid-binding solid phase and the solution, the nucleic acid-binding solid phase is washed. When washing the nucleic acid-binding solid phase, a washing reagent is brought into contact with the nucleic acid-binding solid phase. The reagent for washing is not particularly limited as long as it can remove the reagent added in Step 1 and Step 2 from the nucleic acid-binding solid phase while maintaining the binding of the nucleic acid to the nucleic acid-binding solid phase. Good. As the reagent for washing, for example, a solution containing ethyl alcohol, isopropyl alcohol and the like at a concentration of 70% or more can be used. Further, when the nucleic acid recovered by this method is used for PCR or the like, it is preferable that ethyl alcohol, isopropyl alcohol, and the like contained in the reagent for washing are made as low as possible within a range having a washing effect. . As a result, it is possible to prevent ethyl alcohol, isopropyl alcohol, and the like contained in the cleaning reagent from adversely affecting PCR.

  For example, it is preferable to use 50% ethyl alcohol containing 25 mmol / L potassium acetate as a reagent for washing. By using 50% ethyl alcohol containing 25 mmol / L potassium acetate as a washing reagent, it is possible to prevent components contained in the washing reagent from adversely affecting PCR.

  Next, in step 5, the nucleic acid is eluted from the nucleic acid-binding solid phase washed in step 4. In Step 5, first, the nucleic acid-binding solid phase washed in Step 4 is brought into contact with the first eluent, and the RNA is nucleic acid-binding at a temperature higher than the temperature at which DNA can be effectively eluted from the nucleic acid-binding solid phase. The treatment is carried out in a temperature range below the temperature at which the solid phase can be effectively eluted (hereinafter referred to as the first temperature range). At this time, the first eluent is not particularly limited as long as it has an action of eluting DNA from the nucleic acid-binding solid phase, and a conventionally known eluent can be used. As the first eluent, for example, a low salt concentration aqueous solution or pure water can be used. In particular, it is preferable to use a solution composed of 10 mmol / L Tris (pH 8.5) and 0.1 mmol / L EDTA as the first eluent.

  In step 5, by treating the nucleic acid-binding solid phase in the first eluent within the first temperature range, DNA is mainly eluted from the nucleic acid bound to the nucleic acid-binding solid phase. Step 5 maintains the binding of the majority of RNA bound to the nucleic acid binding solid phase to the nucleic acid binding solid phase by treating the nucleic acid binding solid phase in the first eluent at a first temperature range. it can. Therefore, by performing Step 5, the first eluent mainly contains DNA in the nucleic acid bound to the nucleic acid-binding solid phase. The solution mainly containing the DNA obtained here can be used in the next step as it is, but it is also possible to obtain a higher-purity DNA solution by adding an RNA-degrading enzyme not containing a DNA-degrading enzyme. is there. Ribonuclease A is desirable as the RNase used at this time. Moreover, since mainly DNA is included at this time, the amount of RNase added can be reduced.

  As a new finding regarding the binding characteristics between DNA and RNA and a nucleic acid-binding solid phase, the present inventor has determined that the temperature range suitable for elution of DNA from a nucleic acid-binding solid phase is the temperature range of RNA from a nucleic acid-binding solid phase. It has been found to be significantly below the temperature range suitable for elution. Therefore, DNA can be selectively eluted by treating in the first temperature range described above.

  Here, the temperature range (first temperature range) above the temperature at which DNA can be effectively eluted from the nucleic acid-binding solid phase and below the temperature at which RNA can be effectively eluted from the nucleic acid-binding solid phase. Means a temperature range in which the elution rate of RNA bound to the nucleic acid-binding solid phase is 10% or less. More specifically, the first temperature range is preferably a temperature range of 4 ° C. or higher and 20 ° C. or lower, and more preferably a temperature range of 15 ° C. or higher and 20 ° C. or lower.

  Further, here, the first temperature range means that a nucleic acid-binding solid phase in which equal amounts of DNA and RNA are bound is used, and the temperature conditions are changed in a standard eluent (a solution containing EDTA and Tris). It can also be defined as a temperature range in which when the nucleic acid is eluted, the RNA content contained in the eluent is 50% or less compared to the DNA content.

  When the nucleic acid to be collected is DNA, the above steps 1 to 5 can finally obtain a solution mainly containing DNA and hardly containing RNA. Step 6 is performed when DNA and RNA are selectively recovered or when RNA is recovered without containing DNA.

  In step 6, the nucleic acid-binding solid phase from which most of the DNA has been eluted in step 5 is added to the second eluent, and a temperature range above the temperature at which RNA can be effectively eluted from the nucleic acid-binding solid phase ( Hereinafter, it is referred to as a second temperature range. At this time, the nucleic acid-binding solid phase after the processing in step 5 may be washed in the same manner as in step 4 and then the processing in step 6 may be performed, or step 6 may be performed without performing the cleaning processing. .

  The second eluent is not particularly limited as long as it has an action of eluting RNA from a nucleic acid-binding solid phase, and a conventionally known eluent can be used in the same manner as the first eluent. The second eluent may be the same component as the first eluent. As the second eluent, for example, a low salt concentration aqueous solution or pure water can be used.

  In particular, it is preferable to use a solution composed of 10 mmol / L bicine (pH 8.5) and 0.1 mmol / L EDTA as the second eluent.

  Here, the second temperature range means a temperature range in which the elution rate of RNA bound to the nucleic acid-binding solid phase is 70% or more. More specifically, the second temperature range is preferably 40 ° C. or higher, and more preferably 40 ° C. to 70 ° C. In Step 6, the RNA or nucleic acid-binding solid phase can be prevented from being decomposed by treatment at a temperature of 80 ° C. or lower.

  In Step 6, RNA bound to the nucleic acid-binding solid phase can be mainly eluted by treating the nucleic acid-binding solid phase in the second eluent at the second temperature range. At this time, the DNA that remains bound without being eluted from the nucleic acid-binding solid phase in the process of Step 5 is also eluted in Step 6. However, by sufficiently eluting the DNA in the process of Step 5, Step 6 The solution obtained by this treatment will mainly contain RNA. The solution mainly containing RNA obtained here can be used for the next step as it is, but it is also possible to add a DNA-degrading enzyme not containing RNA-degrading enzyme to obtain a higher-purity RNA solution. is there. As the DNA degrading enzyme used in this case, deoxyribonuclease I is desirable. In addition, since RNA is mainly contained at this time, the amount of the DNA degrading enzyme added can be reduced.

  As described above, by performing steps 5 and 6, DNA and RNA can be selectively recovered from the same nucleic acid-containing substance in a series of steps. That is, one nucleic acid-containing sample may not be divided into DNA collection and RNA collection. Therefore, even if the nucleic acid-containing substance that can be used in Step 1 is a very small amount, DNA and RNA can be reliably and reliably recovered.

  On the other hand, the processing in step 5 and step 6 can be performed in a temperature-controlled processing container 20, for example, as shown in FIG. The processing container 20 is disposed in a recess formed in the temperature control block 21 and can hold a solution therein. Moreover, the processing container 20 can put the nucleic acid capture chip 100 shown in FIG. Since the inside of the processing container 20 is temperature-controlled by the temperature control block 21, a solution having a desired temperature can be stored.

  The processing container 20 may be formed of any material as long as it can hold the liquid inside, but is preferably formed of a material having high thermal conductivity. Furthermore, it is preferable that the processing container 20 is thinly formed in order to efficiently transfer heat from the temperature control block 21 to the liquid stored in the processing container 20.

  The temperature control block 21 is in contact with a heat source 22 made of a Peltier element or the like. The temperature control block 21 is adjusted to a desired temperature by the heat source 22. The temperature of the heat source 22 is controlled by the control device 23 and set to a desired temperature. Further, a temperature sensor 24 is attached to the temperature control block 21. The control device 23 feedback-controls the temperature of the temperature control block 21 based on the temperature of the temperature control block 21 measured by the temperature sensor 24.

  The material of the temperature control block 21 is not particularly limited, but a material having excellent thermal conductivity, such as a metal material, can be used. Further, the temperature control block 21 may be made of an amorphous material whose temperature can be controlled by the heat source 22. Further, when the liquid in the processing container is not controlled below room temperature, the heat source 22 may have only a heater function.

  As described above, for example, the first eluent and the second eluent are injected into the temperature-controlled processing container 20 as shown in FIG. 3, and steps 5 and 6 are performed under strict temperature control. As described above, DNA and RNA can be selectively recovered.

  EXAMPLES Hereinafter, although this invention is demonstrated in detail using an Example, the technical scope of this invention is not limited to a following example.

[Example 1]
In this example, DNA and RNA were captured using the nucleic acid capture chip 100 shown in FIG. 2, and then the elution temperature was changed and DNA and RNA were collected.

  Serum from a hepatitis B patient was used as a treatment sample for DNA recovery. 700 μL of the first reagent was added to 200 μL of serum, stirred, and allowed to stand at room temperature for 10 minutes to dissolve the virus. Here, the first reagent includes 8% Triton X-100 (manufactured by LKB), 5.5 mol / L guanidine thiocyanate (manufactured by Wako Pure Chemical Industries, Ltd., for biochemistry) (2- Morpholino-ethanesulfonic acid: 2-morpholinoethanesulfonic acid (manufactured by Dojindo Laboratories) buffer solution was used.

  After leaving for 10 minutes, 100 μL of the second reagent was added and stirred, and then suction and discharge were performed 20 times by the nucleic acid capture chip 100 shown in FIG. 2 attached to the syringe.

  At this time, an operation was performed such that the liquid surface of the mixed solution did not pass through the blocking member 101a during suction and did not pass through the blocking member 101b during discharge. Here, the second reagent is MES containing 1% Triton X-100 (manufactured by LKB), 5.0 mol / L guanidine thiocyanate (manufactured by Wako Pure Chemical Industries, Ltd., for biochemistry). A buffer solution was used.

  After 20 times of suction and discharge, the waste liquid operation was performed by syringe operation until the liquid level of the mixed liquid did not pass through the blocking member 101b from the nucleic acid capturing chip. After waste of the mixed solution, the second reagent 900 μL was aspirated and discharged five times with the nucleic acid capture chip 100 by a syringe operation. At this time, an operation was performed such that the liquid surface of the mixed solution did not pass through the blocking member 101a during suction and did not pass through the blocking member 101b during discharge. After the second reagent was discarded, the third reagent 900 μL was aspirated and discharged five times with the nucleic acid capture chip 100 by a syringe operation. Here, 50% ethanol (made by Wako Pure Chemical Industries, Ltd., reagent special grade) containing 25 mmol / L potassium acetate (made by Wako Pure Chemical Industries, Ltd., reagent special grade) was used as the third reagent.

  After suction and discharge five times, the entire liquid was drained from the nucleic acid capture chip 100 by a syringe operation, and the solution remaining inside the nucleic acid capture chip 100 was removed by an exhaust operation. After removal, washing with the third reagent was repeated again. After the second evacuation operation, the nucleic acid-capturing chip 100 was subjected to suction and discharge operations of 60 μL of the first eluent controlled at a predetermined temperature by a block incubator (FIG. 3) by syringe operation 20 times. Here, the first eluent includes 10 mmol / L Tris (manufactured by Dojindo Laboratories) buffer solution containing 0.1 mmol / L ethylenediaminetetraacetic acid (manufactured by Nippon Gene, for genetic engineering research) ( pH 8.5) was used. Then, after 20 suction and discharge operations, the concentration of DNA contained in the first eluent was measured, and the elution rate of DNA was calculated.

  On the other hand, the processing sample for RNA recovery was performed using the serum of a hepatitis C patient and the same processing procedure as that for recovering the hepatitis B virus gene. In the RNA recovery, the second eluent was used instead of the first eluent. The second eluent was a 10 mmol / L bicine (manufactured by Dojindo Laboratories) buffer solution (pH 8.5) containing 0.1 mmol / L ethylenediaminetetraacetic acid (manufactured by Nippon Gene, for genetic engineering research). )It was used. Then, the concentration of RNA contained in the second eluent was measured, and the elution rate of RNA was calculated.

  FIG. 4 shows the relationship between the temperature of the first eluent and the elution rate of DNA, and the relationship between the temperature of the second eluent and the elution rate of RNA. In FIG. 4, the relationship between the temperature of the first eluent and the elution rate of DNA is indicated by a broken line, and the relationship between the temperature of the second eluent and the elution rate of RNA is indicated by a solid line.

  As shown in FIG. 4, it became clear that DNA and RNA have different temperature ranges suitable for elution from a nucleic acid-binding solid phase. In particular, it was found that DNA begins to elute at a relatively low temperature, whereas RNA begins to elute at a relatively high temperature. Therefore, the nucleic acid-binding solid phase to which the nucleic acid is bound is treated at a temperature above the temperature at which DNA can be effectively eluted from the nucleic acid-binding solid phase and below the temperature at which RNA can be effectively eluted from the nucleic acid-binding solid phase. Thus, it was found that DNA can be mainly recovered in the first eluent. In addition, it has been clarified that RNA can be mainly recovered in the second eluent by treating the nucleic acid-binding solid phase after recovering DNA at a temperature higher than the temperature at which RNA can be eluted from the nucleic acid-binding solid phase. It was.

  From these results, the nucleic acid-binding solid phase is brought into contact with a sample containing DNA and RNA, and the temperature of the eluent is controlled even when DNA and RNA are captured on the nucleic acid-binding solid phase. As a result, it was revealed that DNA and RNA can be selectively recovered.

  In particular, as can be seen from FIG. 4, it can be seen that DNA can be mainly recovered by treating a nucleic acid-binding solid phase on which DNA and RNA have been captured in an eluent at a temperature of 4 ° C. or higher and 20 ° C. or lower. Further, as can be seen from FIG. 4, the RNA captured on the nucleic acid-binding solid phase can be recovered by treating the nucleic acid-binding solid phase after recovering the DNA in an eluent at 40 ° C. or higher. I understand.

It is a flowchart which shows the nucleic acid collection | recovery method to which this invention is applied. It is sectional drawing of a nucleic acid capture chip. It is a figure which shows roughly the structure of the apparatus used when eluting the nucleic acid capture | acquired by the nucleic acid binding solid phase. It is a characteristic view which shows the relationship between the elution rate of DNA and RNA, and temperature.

Explanation of symbols

100 ... Nucleic acid capture chip, 102 ... Nucleic acid binding solid phase

Claims (4)

A first step of contacting a nucleic acid-binding solid phase with a sample containing ribonucleic acid and deoxyribonucleic acid;
A first eluent at 4 ° C. or higher and 20 ° C. or lower is brought into contact with a nucleic acid-binding solid phase capturing ribonucleic acid and deoxyribonucleic acid contained in the sample, and at least deoxyribonucleic acid is eluted from the first eluent. Two steps ,
A nucleic acid recovery method comprising a third step of bringing the nucleic acid-binding solid phase into contact with a second eluent having a temperature higher than that of the first eluent, and eluting at least ribonucleic acid into the second eluent .   The nucleic acid recovery method according to claim 1, wherein a reagent for reducing ribonucleic acid is mixed with at least the first eluate from which deoxyribonucleic acid has been eluted. The second eluent least ribonucleic acid is eluted, the nucleic acid recovery method of claim 1 wherein mixing the reagents to decrease the deoxyribonucleic acid.   The nucleic acid recovery method according to claim 1, wherein the nucleic acid-binding solid phase is a substance containing quartz.

Images